NCT05103397

Brief Summary

To compare the effect of low dose methylprednisolone versus high dose on inflammatory mediators' level and cardioprotective effect after CPB in correction of congenital acyanotic heart disease.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
75

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Oct 2021

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 16, 2021

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

October 22, 2021

Completed
11 days until next milestone

First Posted

Study publicly available on registry

November 2, 2021

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2022

Completed
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2022

Completed
Last Updated

November 2, 2021

Status Verified

October 1, 2021

Enrollment Period

3 months

First QC Date

October 22, 2021

Last Update Submit

November 1, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • assessment of Level of IL 6 after CPB time

    comparing level of IL6 in different groups after CPB

    3 months

Secondary Outcomes (1)

  • Less postoperative complications related to high doses of steroid represented as blood glucose level.

    3 months

Study Arms (3)

low dose group

ACTIVE COMPARATOR

low dose group. Group (A) (25 patients) patients will receive 10 mg/Kg methyl prednisolone after induction before separation to (CPB).

Drug: methyl prednisolone

high dose group

ACTIVE COMPARATOR

high dose group. Group (B) (25 patients) patients will receive 30 mg/Kg methyl prednisolone after induction before separation to (CPB).

Drug: Methyl Prednisolonate

Placebo group

PLACEBO COMPARATOR

placebo group. Group (C) (control group)(25 patients) patients will receive placebo in form of normal saline.

Drug: Placebo

Interventions

Low dose group .Group (A) 10 mg/Kg methyl prednisolone will be received after induction and before separation to (CPB).

Also known as: steroid
low dose group

High dose group.Group (B) 30 mg/Kg will be received after induction and before separation (CPB)

Also known as: steroid
high dose group

Placebo group.Group (C) (25 patients) patients will receive placebo in form of normal saline

Placebo group

Eligibility Criteria

Age1 Year - 16 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • We will include pediatric patients ( 1- 16) years old undergoing surgical correction for congenital acyanotic cardiac lesions needing cardiopulmonary bypass machine.

You may not qualify if:

  • \) Cyanotic heart disease. 2) Closed cardiac surgeries. 3) Previous cardiac surgery. 4) Patients suffering neurological illness. 5) Diabetics. 6) Emergency procedures. 7) Patients on preoperative steroid therapy. 8) Adult patients with congenital heart disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samar mohammed

Cairo, Egypt

RECRUITING

MeSH Terms

Interventions

Steroidsmethyl prednisolonate

Intervention Hierarchy (Ancestors)

Fused-Ring CompoundsPolycyclic Compounds

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of anesthesia

Study Record Dates

First Submitted

October 22, 2021

First Posted

November 2, 2021

Study Start

October 16, 2021

Primary Completion

January 15, 2022

Study Completion

January 30, 2022

Last Updated

November 2, 2021

Record last verified: 2021-10

Locations